All In Biotech

Drug Trial Radar · NCT03530345

Efficacy and Safety of Intravenous Neridronic Acid in CRPS

Randomized, Double-blind, Placebo-controlled Trial Investigating the Efficacy and Safety of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome (CRPS)

Last checked: Nov 19, 2026Latest source record: Aug 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 182 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

182

Actual

Start

May 30, 2018

Primary completion

Jul 31, 2019

Study completion Jul 31, 2019

Sponsor

Lead sponsor
Grünenthal GmbHIndustry
Sponsor type
Industry
First posted
May 21, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this trial was to investigate the efficacy and safety of intravenous neridronic acid in subjects with Complex Regional Pain Syndrome (CRPS). The trial consisted of an Enrollment Period lasting up to 60 days, Treatment Period A consisting of 4 infusions (neridronic acid or placebo) over 10 days, and a Follow-up Period 1 until Week 26. At Week 26, participants not meeting the pre-specified criteria to continue into Treatment Period B continued in Follow-up Period 2 until Week 52. Participants meeting the pre-specified criteria entered the open-label Treatment Period B with 4 additional infusions (neridronic acid) over 10 days and follow-up visits until Week 52.

Conditions

  • Complex Regional Pain Syndrome (CRPS)

Interventions

  • Neridronic acid 100 mgDrug

    100 mg neridronic acid supplied in glass vials in 8 mL of excipients.

  • PlaceboDrug

    Glass vials with matching placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 12 in the Average Pain Intensity Score (Weekly Average of Pain Values Recorded Daily in the Electronic Diary)Time frame: From the Baseline Phase (Day -7 to Day -1) to Week 12

Locations

71 sites in 7 countries. Site status is shown where the registry gives one.

  • US015 - Tennessee Valley Pain Consultants

    Huntsville, Alabama

  • US043 - Horizon Research Partners

    Mobile, Alabama

  • US045 - Holland Center for Family Health

    Peoria, Arizona

  • US003 - HealthStar Research

    Hot Springs, Arkansas

  • US049 - Orange County Research Institute

    Anaheim, California

  • US053 - Core Healthcare Group

    Cerritos, California

  • US013 - Inland Pain Medicine

    Colton, California

  • US044 - The Helm Center for Pain Management

    Laguna Woods, California

  • US052 - Providere' Research Inc.

    West Covina, California

  • US036 - Denver Back Pain Specialists

    Greenwood Village, Colorado

  • US007 - Neurology Offices of South Florida

    Boca Raton, Florida

  • US030 - Gulfcoast Clinical Research Center

    Fort Myers, Florida

  • US004 - The Chappel Group Research

    Kissimmee, Florida

  • US023 - AGR Research

    Lake Worth, Florida

  • US020 - SIMEDHealth

    Ocala, Florida

  • US012 - NeuroMedical Research Center

    Panama City, Florida

  • US046 - Clinical Research of West Florida, Inc.

    Tampa, Florida

  • US027 - Drug Studies America

    Marietta, Georgia

  • US041 - Better Health Clinical Research, Inc.

    Newnan, Georgia

  • US032 - Millennium Pain Center

    Bloomington, Illinois

  • US011 - Otrimed Corporation

    Edgewood, Kentucky

  • US040 - Regeneris Medical

    North Attleboro, Massachusetts

  • Us054 - Aa Mrc

    Flint, Michigan

  • US025 - Oakland Medical Research

    Troy, Michigan

  • US009 - Elite Clinical Research

    Jackson, Mississippi

  • US017 - Jackson Anesthesia Pain Center

    Jackson, Mississippi

  • US033 - Galen Research

    Chesterfield, Missouri

  • US050 - Premier Pain Centers

    Shrewsbury, New Jersey

  • US029 - Dent Neurologic Institute

    Amherst, New York

  • US038 - DiGiovanna Institute For Medical Education

    North Massapequa, New York

  • US022 - The Neurological Institute

    Charlotte, North Carolina

  • US047 - The Center for Clinical Research

    Winston-Salem, North Carolina

  • US005 - Hometown Urgent Care and Research

    Dayton, Ohio

  • US021 - SP Research PLLC

    Oklahoma City, Oklahoma

  • US028 - Founders Research Corporation

    Philadelphia, Pennsylvania

  • US018 - Carolinas Center for Advanced Management of Pain

    Spartanburg, South Carolina

  • US055 - Diversified Medical Practices

    Houston, Texas

  • US048 - Axios Research

    Salt Lake City, Utah

  • US037 - Clinical Research Partners

    Richmond, Virginia

  • AU002 - Royal North Shore Hospital Michael J Cousins Pain Management and Research Centre

    St Leonards, New South Wales, Australia

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.